Evidence map›Paper›PMID 33808201›Full record

ReviewCancers2021

Human NK Cells in Autologous Hematopoietic Stem Cell Transplantation for Cancer Treatment.

Ane Orrantia, Iñigo Terrén, Gabirel Astarloa-Pando, Olatz Zenarruzabeitia, Francisco Borrego

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Targeting the myeloid microenvironment in neuroblastoma.Journal of experimental & clinical cancer research : CR · 2023
    Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ane OrrantiaImmunopathology Group, Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.ORCID 0000-0002-9016-3799
Iñigo TerrénImmunopathology Group, Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.ORCID 0000-0002-8099-3916
Gabirel Astarloa-PandoImmunopathology Group, Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Olatz ZenarruzabeitiaImmunopathology Group, Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.ORCID 0000-0002-0869-9034
Francisco BorregoImmunopathology Group, Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.ORCID 0000-0002-3105-981X
BioCruces Health research Institute · ESIkerbasque · ES

Funding

Fundación Científica Asociación Española Contra el Cáncer PROYE16074BORRFundación Jesús de Gangoiti Barrera FJGB20/002Fundación Jesús de Gangoiti Barrera FJGB20/007Hezkuntza, Hizkuntza Politika Eta Kultura Saila, Eusko Jaurlaritza PRE_2020_2_0007Ikerbasque, Basque Foundation for ScienceInstituto de Salud Carlos III CD17/00128Osasun Saila, Eusko Jaurlaritzako 2020333024
6 · The paper itself

Abstract

Natural killer (NK) cells are phenotypically and functionally diverse lymphocytes with the ability to recognize and kill malignant cells without prior sensitization, and therefore, they have a relevant role in tumor immunosurveillance. NK cells constitute the main lymphocyte subset in peripheral blood in the first week after hematopoietic stem cell transplantation (HSCT). Although the role that NK cells play in allogenic HSCT settings has been documented for years, their significance and beneficial effects associated with the outcome after autologous HSCT are less recognized. In this review, we have summarized fundamental aspects of NK cell biology, such as, NK cell subset diversity, their effector functions, and differentiation. Moreover, we have reviewed the factors that affect autologous HSCT outcome, with particular attention to the role played by NK cells and their receptor repertoire in this regard.

Indexed as

autologous HSCTgraft versus leukemiagraft versus tumorhematopoietic stem cell transplantation (HSCT)HLAKIRmultiple myelomaNK cellsnon-Hodgkin lymphoma

Identifiers

PMID33808201
PMCPMC8037172
OpenAlexW3151871206

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.